Alnylam Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Alnylam Pharmaceuticals Inc cash flow-to-debt ratio. Alnylam Pharmaceuticals Inc (ALNY) has a Cash Flow-to-Debt Ratio of 0.04x as of December 2025, meaning its operating cash flow of $163.56 Million could theoretically repay 0% of its total liabilities ($4.18 Billion) in one year. Check ALNY cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Alnylam Pharmaceuticals Inc (2002–2025)
Cash flow-to-debt ratio of Alnylam Pharmaceuticals Inc from 2002 to 2025. Historical debt coverage capacity for Alnylam Pharmaceuticals Inc across 24 annual periods. Check Alnylam Pharmaceuticals Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Alnylam Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2002–2025)
Alnylam Pharmaceuticals Inc cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Alnylam Pharmaceuticals Inc. For the full cash flow conversion analysis, see Alnylam Pharmaceuticals Inc (ALNY) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | $524.08 Million | $4.18 Billion | ▲ +6398.7% |
| 2024 | 0.00x | $-8.31 Million | $4.17 Billion | ▼ -107.7% |
| 2023 | 0.03x | $104.16 Million | $4.05 Billion | ▲ +117.6% |
| 2022 | -0.15x | $-541.27 Million | $3.70 Billion | ▲ +30.4% |
| 2021 | -0.21x | $-641.69 Million | $3.06 Billion | ▲ +18.3% |
| 2020 | -0.26x | $-614.96 Million | $2.39 Billion | ▲ +11.6% |
| 2019 | -0.29x | $-278.43 Million | $956.44 Million | ▲ +85.9% |
| 2018 | -2.06x | $-562.62 Million | $272.84 Million | ▼ -23.0% |
| 2017 | -1.68x | $-382.79 Million | $228.30 Million | ▼ -86.7% |
| 2016 | -0.90x | $-307.70 Million | $342.59 Million | ▲ +42.2% |
| 2015 | -1.55x | $-189.14 Million | $121.80 Million | ▼ -34.4% |
| 2014 | -1.16x | $-165.64 Million | $143.33 Million | ▼ -152.8% |
| 2013 | -0.46x | $-68.66 Million | $150.18 Million | ▲ +39.3% |
| 2012 | -0.75x | $-115.61 Million | $153.47 Million | ▼ -41.8% |
| 2011 | -0.53x | $-87.07 Million | $163.92 Million | ▼ -48.0% |
| 2010 | -0.36x | $-84.34 Million | $235.03 Million | ▼ -50.9% |
| 2009 | -0.24x | $-72.14 Million | $303.42 Million | ▼ -228.0% |
| 2008 | 0.19x | $65.49 Million | $352.55 Million | ▼ -72.2% |
| 2007 | 0.67x | $196.52 Million | $294.62 Million | ▲ +205.2% |
| 2006 | -0.63x | $-24.63 Million | $38.83 Million | ▼ -40.7% |
| 2005 | -0.45x | $-16.48 Million | $36.57 Million | ▲ +54.0% |
| 2004 | -0.98x | $-19.57 Million | $19.96 Million | ▼ -372.9% |
| 2003 | -0.21x | $-12.83 Million | $61.89 Million | ▼ -236.6% |
| 2002 | -0.06x | $-1.28 Million | $20.76 Million | — |